Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice.

@article{Schreiber2007LongtermEO,
  title={Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice.},
  author={Stephan A Schreiber and Anika Russmann},
  journal={Current medical research and opinion},
  year={2007},
  volume={23 12},
  pages={3131-6}
}
OBJECTIVE To investigate the effect of initiating insulin glargine (glargine: LANTUS), a once-daily basal insulin analogue, plus an educational programme, on glycaemic control and body weight in patients with type 1 diabetes in clinical practice. RESEARCH DESIGN AND METHODS A retrospective analysis of the medical records of 65 patients (mean age: 40.7 +/- 13.3 years) with type 1 diabetes was performed. Patients had previously been treated with NPH insulin (NPH; n = 54) or NPH insulin + lente… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
In this retrospective study of medical records , patients with type 1 diabetes treated with insulin glargine over 30 months in combination with educational support and close clinical supervision decreased their HbA(1c ) levels without weight gain versus previous treatment with NPH insulin or insulin lente .
In this retrospective study of medical records , patients with type 1 diabetes treated with insulin glargine over 30 months in combination with educational support and close clinical supervision decreased their HbA(1c ) levels without weight gain versus previous treatment with NPH insulin or insulin lente .
To investigate the effect of initiating insulin glargine ( glargine : LANTUS ) , a once - daily basal insulin analogue , plus an educational programme , on glycaemic control and body weight in patients with type 1 diabetes in clinical practice .
To investigate the effect of initiating insulin glargine ( glargine : LANTUS ) , a once - daily basal insulin analogue , plus an educational programme , on glycaemic control and body weight in patients with type 1 diabetes in clinical practice .
To investigate the effect of initiating insulin glargine ( glargine : LANTUS ) , a once - daily basal insulin analogue , plus an educational programme , on glycaemic control and body weight in patients with type 1 diabetes in clinical practice .
Long - term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice .
Long - term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice .
No episodes of severe hypoglycaemia ( blood glucose < 40 mg / dL [ < 2.2 mmol / L ] occurred .
No episodes of severe hypoglycaemia ( blood glucose < 40 mg / dL [ < 2.2 mmol / L ] occurred .
HypoglycemiaMay be treated byGlucose
No episodes of severe hypoglycaemia ( blood glucose < 40 mg / dL [ < 2.2 mmol / L ] occurred .
Patients had previously been treated with NPH insulin ( NPH ; n = 54 ) or NPH insulin + lente insulin ( NPH + lente ; n = 11 ) and then received glargine once daily ( bedtime ) , plus short - acting prandial insulin , for 30 months .
Patients had previously been treated with NPH insulin ( NPH ; n = 54 ) or NPH insulin + lente insulin ( NPH + lente ; n = 11 ) and then received glargine once daily ( bedtime ) , plus short - acting prandial insulin , for 30 months .
In this retrospective study of medical records , patients with type 1 diabetes treated with insulin glargine over 30 months in combination with educational support and close clinical supervision decreased their HbA(1c ) levels without weight gain versus previous treatment with NPH insulin or insulin lente .
In this retrospective study of medical records , patients with type 1 diabetes treated with insulin glargine over 30 months in combination with educational support and close clinical supervision decreased their HbA(1c ) levels without weight gain versus previous treatment with NPH insulin or insulin lente .
Patients had previously been treated with NPH insulin ( NPH ; n = 54 ) or NPH insulin + lente insulin ( NPH + lente ; n = 11 ) and then received glargine once daily ( bedtime ) , plus short - acting prandial insulin , for 30 months .
Patients had previously been treated with NPH insulin ( NPH ; n = 54 ) or NPH insulin + lente insulin ( NPH + lente ; n = 11 ) and then received glargine once daily ( bedtime ) , plus short - acting prandial insulin , for 30 months .
Patients had previously been treated with NPH insulin ( NPH ; n = 54 ) or NPH insulin + lente insulin ( NPH + lente ; n = 11 ) and then received glargine once daily ( bedtime ) , plus short - acting prandial insulin , for 30 months .
Patients had previously been treated with NPH insulin ( NPH ; n = 54 ) or NPH insulin + lente insulin ( NPH + lente ; n = 11 ) and then received glargine once daily ( bedtime ) , plus short - acting prandial insulin , for 30 months .
In this retrospective study of medical records , patients with type 1 diabetes treated with insulin glargine over 30 months in combination with educational support and close clinical supervision decreased their HbA(1c ) levels without weight gain versus previous treatment with NPH insulin or insulin lente .
In this retrospective study of medical records , patients with type 1 diabetes treated with insulin glargine over 30 months in combination with educational support and close clinical supervision decreased their HbA(1c ) levels without weight gain versus previous treatment with NPH insulin or insulin lente .
Patients had previously been treated with NPH insulin ( NPH ; n = 54 ) or NPH insulin + lente insulin ( NPH + lente ; n = 11 ) and then received glargine once daily ( bedtime ) , plus short - acting prandial insulin , for 30 months .
Patients had previously been treated with NPH insulin ( NPH ; n = 54 ) or NPH insulin + lente insulin ( NPH + lente ; n = 11 ) and then received glargine once daily ( bedtime ) , plus short - acting prandial insulin , for 30 months .
In this retrospective study of medical records , patients with type 1 diabetes treated with insulin glargine over 30 months in combination with educational support and close clinical supervision decreased their HbA(1c ) levels without weight gain versus previous treatment with NPH insulin or insulin lente .
In this retrospective study of medical records , patients with type 1 diabetes treated with insulin glargine over 30 months in combination with educational support and close clinical supervision decreased their HbA(1c ) levels without weight gain versus previous treatment with NPH insulin or insulin lente .
In this retrospective study of medical records , patients with type 1 diabetes treated with insulin glargine over 30 months in combination with educational support and close clinical supervision decreased their HbA(1c ) levels without weight gain versus previous treatment with NPH insulin or insulin lente .
In this retrospective study of medical records , patients with type 1 diabetes treated with insulin glargine over 30 months in combination with educational support and close clinical supervision decreased their HbA(1c ) levels without weight gain versus previous treatment with NPH insulin or insulin lente .
Patients had previously been treated with NPH insulin ( NPH ; n = 54 ) or NPH insulin + lente insulin ( NPH + lente ; n = 11 ) and then received glargine once daily ( bedtime ) , plus short - acting prandial insulin , for 30 months .
Patients had previously been treated with NPH insulin ( NPH ; n = 54 ) or NPH insulin + lente insulin ( NPH + lente ; n = 11 ) and then received glargine once daily ( bedtime ) , plus short - acting prandial insulin , for 30 months .
In this retrospective study of medical records , patients with type 1 diabetes treated with insulin glargine over 30 months in combination with educational support and close clinical supervision decreased their HbA(1c ) levels without weight gain versus previous treatment with NPH insulin or insulin lente .
In this retrospective study of medical records , patients with type 1 diabetes treated with insulin glargine over 30 months in combination with educational support and close clinical supervision decreased their HbA(1c ) levels without weight gain versus previous treatment with NPH insulin or insulin lente .
To investigate the effect of initiating insulin glargine ( glargine : LANTUS ) , a once - daily basal insulin analogue , plus an educational programme , on glycaemic control and body weight in patients with type 1 diabetes in clinical practice .
To investigate the effect of initiating insulin glargine ( glargine : LANTUS ) , a once - daily basal insulin analogue , plus an educational programme , on glycaemic control and body weight in patients with type 1 diabetes in clinical practice .
To investigate the effect of initiating insulin glargine ( glargine : LANTUS ) , a once - daily basal insulin analogue , plus an educational programme , on glycaemic control and body weight in patients with type 1 diabetes in clinical practice .
To investigate the effect of initiating insulin glargine ( glargine : LANTUS ) , a once - daily basal insulin analogue , plus an educational programme , on glycaemic control and body weight in patients with type 1 diabetes in clinical practice .
To investigate the effect of initiating insulin glargine ( glargine : LANTUS ) , a once - daily basal insulin analogue , plus an educational programme , on glycaemic control and body weight in patients with type 1 diabetes in clinical practice .
To investigate the effect of initiating insulin glargine ( glargine : LANTUS ) , a once - daily basal insulin analogue , plus an educational programme , on glycaemic control and body weight in patients with type 1 diabetes in clinical practice .
To investigate the effect of initiating insulin glargine ( glargine : LANTUS ) , a once - daily basal insulin analogue , plus an educational programme , on glycaemic control and body weight in patients with type 1 diabetes in clinical practice .
To investigate the effect of initiating insulin glargine ( glargine : LANTUS ) , a once - daily basal insulin analogue , plus an educational programme , on glycaemic control and body weight in patients with type 1 diabetes in clinical practice .
To investigate the effect of initiating insulin glargine ( glargine : LANTUS ) , a once - daily basal insulin analogue , plus an educational programme , on glycaemic control and body weight in patients with type 1 diabetes in clinical practice .
All Topics